Supercharging Immunotherapy

19 Oct 2020

Jean-Charles Soria, M.D., Ph.D., is Professor of Medicine and Medical Oncology at the University of Paris-Saclay and currently serves as Director General of the Gustave Roussy Cancer Center.
Read More

all news

fancy black and blue t-cell 3d scientific images immune system

We work to reprogram the immune system to more effectively combat cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring. We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.

Supercharging Immunotherapy

News

HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of…

HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and…

HOOKIPA Pharma Reports Third Quarter 2020 Financial Results and Provides a…

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in November

HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for…

HOOKIPA Appoints Prof. Jean-Charles Soria to its Board of Directors

Our Mission

Our Pipeline

Careers